David Zhu
SlowingNamed in filings at Kendall Capital PartnersOn the current fund
- Board seats filed
- 4
- Named on a board
all filings on record
Named in filings at Kendall Capital PartnersOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Rejuvenate Bio | Biotech & pharma | June 2026 | None on file |
| Omnipulse Biosciences | Biotech & pharma | December 2023 | None on file |
| Bilayer Therapeutics | Biotech & pharma | April 2021 | None on file |
| EpiBone | Biotech & pharma | February 2021 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name David Zhu on the board, based on 4 filed seats with a verified or cited source.